BAK1

Bcl-2 homologous antagonist/killer

33,039 patent compounds predicted against BAK1, 15,303 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL300853	0.97	6/20
Gingkolic Acid (SCHEMBL163525)	0.95	6/20
SCHEMBL154719	0.85	6/20
Anacardic Acid (SCHEMBL154720)	0.73	6/20
SCHEMBL23277	0.72	6/20
SCHEMBL300614	0.72	6/20
SCHEMBL301487	0.72	6/20
SCHEMBL485756	0.72	6/20
SCHEMBL244743	0.70	6/20
SCHEMBL376922	0.64	6/20
SCHEMBL409185	0.62	6/20
SCHEMBL211983	0.58	6/20
SCHEMBL105964	0.61	5/20
SCHEMBL315846	0.61	5/20
Acrylic Acid (SCHEMBL111782)	0.60	5/20
Methacrylic Acid (SCHEMBL112437)	0.60	5/20
SCHEMBL97903	0.59	5/20
SCHEMBL574314	0.59	5/20
SCHEMBL574395	0.59	5/20
SCHEMBL574605	0.59	5/20

Germline variants in BAK1 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full BAK1 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to BAK1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer	PHASE4	UNKNOWN
Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia	PHASE3	COMPLETED
Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme	PHASE2	COMPLETED
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL	PHASE2	RECRUITING
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma	PHASE2	RECRUITING
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant	PHASE1/PHASE2	RECRUITING
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML	PHASE2	ACTIVE_NOT_RECRUITING
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer	PHASE2	COMPLETED
FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	PHASE2	COMPLETED
Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer	PHASE1/PHASE2	COMPLETED
Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma	PHASE2	ACTIVE_NOT_RECRUITING
Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma	PHASE1/PHASE2	NOT_YET_RECRUITING
Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL	PHASE2	ACTIVE_NOT_RECRUITING
A Clinical Trial of TQB3909 Tablets in Subjects With Advanced Malignant Tumors	PHASE1	UNKNOWN
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN	PHASE1	ACTIVE_NOT_RECRUITING
Gossypol (AT-101) and Temozolomide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme	PHASE1	COMPLETED
Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer	PHASE1	COMPLETED
A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma	PHASE1	COMPLETED
Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS	PHASE1	RECRUITING
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma	PHASE1	ACTIVE_NOT_RECRUITING
In Vivo Lithium Treatment Effects on Gene Expression Levels in Lymphoblastoid Cell Lines From Human Healthy Subjects	PHASE1	COMPLETED
Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia	PHASE1	SUSPENDED
Italian Observational Study of Patients With Acute Myeloid Leukemia Treated With Small Molecule Inhibiting BCL-2	nan	UNKNOWN
Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.	nan	RECRUITING
Determinants of the Response to BTK Degraders (BTKd) in Chronic Lymphocytic Leukemia	nan	RECRUITING
The Effect of TRA-8 on Ovarian Cancer Tissue	nan	COMPLETED
Studying Cells Collected Through Ductal Lavage in Women Undergoing Surgery for Ductal Carcinoma In Situ or Other Breast Cancer	nan	COMPLETED
Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML	nan	RECRUITING
French Observational Study of Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma in Real-World Settings	nan	ACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a BAK1 binder may also engage these)

Protein	Name	Similarity
O08734	—	0.992	O08734 →
O02703	—	0.985	O02703 →
BCL2L1	Bcl-2-like protein 1	0.985	landscape →
O77737	—	0.984	O77737 →
Q6R755	—	0.982	Q6R755 →
Q07816	—	0.982	Q07816 →
Q9JJV8	—	0.982	Q9JJV8 →
Q64373	—	0.982	Q64373 →
P53563	—	0.981	P53563 →
Q4JHS0	—	0.980	Q4JHS0 →
Q63690	—	0.979	Q63690 →
BAX	Apoptosis regulator BAX	0.979	landscape →
BID	BH3-interacting domain death agonist	0.976	landscape →
Q91828	—	0.976	Q91828 →
Q9JLT6	—	0.976	Q9JLT6 →
P49950	—	0.975	P49950 →
Q00709	—	0.975	Q00709 →
Q1RMX3	—	0.975	Q1RMX3 →
P70444	—	0.975	P70444 →
A1L1L2	—	0.974	A1L1L2 →
BCL2	Apoptosis regulator Bcl-2	0.974	landscape →
Q6NUQ4	—	0.973	Q6NUQ4 →
Q07813	—	0.973	Q07813 →
O02718	—	0.973	O02718 →
Q91WR3	—	0.972	Q91WR3 →
Q8BK08	—	0.972	Q8BK08 →
P10417	—	0.971	P10417 →
BCL2L2	Bcl-2-like protein 2	0.971	landscape →
A4FV45	—	0.971	A4FV45 →
Q8BK03	—	0.971	Q8BK03 →